Technology to treat neurological diseases, pain wins Indiana fund’s commercialization award
By Admin | December 02, 2021
WEST LAFAYETTE, Ind. – Technology to provide new options for patients with neurological disease and pain has received major new support.
Neuro Vigor, a Purdue University-affiliated startup, won a $100,000 Early Commercialization Award from the Indiana Spinal Cord and Brain Injury Research Fund. The company’s proprietary drugs offer new disease-modifying therapies to reduce patient suffering in neuro-degenerative conditions. This is the first time the research fund has provided support to an early commercialization company.
“This award is a significant show of support for our company and technologies,” said Mark Van Fleet, CEO of Neuro Vigor. “Our initial target is neuropathic pain in spinal cord injury, a largely unmet medical challenge, but our solution has exciting potential for several other devastating neurological diseases, including Multiple Sclerosis and Parkinson’s.”
Dr. Henry Feuer, neurosurgeon and chairman of the fund’s board, said, “This creation of an early commercialization opportunity as part of our annual funding mechanism recognizes the contributions that established or startup companies could provide.”
“This award, using rigid National Institutes of Health criteria, will enable Neuro Vigor to bring together top scientists and collaborators in order to develop a novel therapeutic strategy to reduce the consequences from neuropathic pain, with fewer side effects.”
Neuro Vigor’s technology is largely based on the work of...(More)
For more info please read, Technology to treat neurological diseases, pain wins Indiana fund’s commercialization award, by Purdue University